Exelixis (EXEL) Stock Forecast and Price Target (2026)

The average target of $54.87 sits below the $62.23 price, -11.8%. The median is $54.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

The published targets span $41.00 to $70.00. That gap is 53% of the average target, which counts as moderate disagreement. That is a fairly typical spread: enough agreement that the average means something, enough disagreement that it should not be treated as precise.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the EXEL is it a buy page.

In the last six months there have been 9 raises and 2 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving. Note the tension here: the average target sits below the current price, yet the recent individual actions have mostly been raises. That usually means the published average has not caught up with the most recent revisions, and it is a good reason not to lean on the average alone.

Of the analysts with a published rating, 7 say buy, 10 say hold, and 1 says sell, so 39% carry a buy. That buy share has fallen over the last three months, so sentiment is drifting more negative.

Read the distribution rather than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

• It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
• The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
• Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
• Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

For the fiscal year ending Dec 2026, the 17 analysts publishing estimates on EXEL expect earnings of $3.58 per share (+16% on the year before) and revenue of $2.6 billion (+10%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Exelixis next reports on October 29, 2026, which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering EXEL do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $4.27 per share, +19% on the fiscal year ending Dec 2026 estimate of $3.58. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of October 2026, EXEL trades at about 19.6 times trailing earnings and 14.6 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Exelixis can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Cabozantinib franchise growth, Zanzalintinib pipeline transition, Profitability and capital returns. The risk cited most often against it is the dominant risk is single-franchise concentration: the large majority of revenue comes from cabozantinib, so any competitive, safety, or reimbursement setback in kidney cancer would hit the whole company.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the EXEL is it a buy page. This page deliberately stops at the numbers.